GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » ROE %

D&D Pharmatech (XKRX:347850) ROE % : -38.02% (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. D&D Pharmatech's annualized net income for the quarter that ended in Jun. 2024 was ₩-23,138 Mil. D&D Pharmatech's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was ₩60,852 Mil. Therefore, D&D Pharmatech's annualized ROE % for the quarter that ended in Jun. 2024 was -38.02%.

The historical rank and industry rank for D&D Pharmatech's ROE % or its related term are showing as below:

XKRX:347850' s ROE % Range Over the Past 10 Years
Min: -192.25   Med: -61.35   Max: 14.03
Current: -9.09

During the past 6 years, D&D Pharmatech's highest ROE % was 14.03%. The lowest was -192.25%. And the median was -61.35%.

XKRX:347850's ROE % is ranked better than
73.8% of 1328 companies
in the Biotechnology industry
Industry Median: -42.745 vs XKRX:347850: -9.09

D&D Pharmatech ROE % Historical Data

The historical data trend for D&D Pharmatech's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech ROE % Chart

D&D Pharmatech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -158.27 -61.35 -43.60 -192.25 14.03

D&D Pharmatech Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24
ROE % -3,980.51 745.20 1.50 4.39 -38.02

Competitive Comparison of D&D Pharmatech's ROE %

For the Biotechnology subindustry, D&D Pharmatech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D&D Pharmatech's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D&D Pharmatech's ROE % distribution charts can be found below:

* The bar in red indicates where D&D Pharmatech's ROE % falls into.



D&D Pharmatech ROE % Calculation

D&D Pharmatech's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=3933.804/( (9440.223+46649.608)/ 2 )
=3933.804/28044.9155
=14.03 %

D&D Pharmatech's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=-23138.184/( (46649.608+75053.909)/ 2 )
=-23138.184/60851.7585
=-38.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


D&D Pharmatech  (XKRX:347850) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-23138.184/60851.7585
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-23138.184 / 9266.272)*(9266.272 / 94364.7385)*(94364.7385 / 60851.7585)
=Net Margin %*Asset Turnover*Equity Multiplier
=-249.7 %*0.0982*1.5507
=ROA %*Equity Multiplier
=-24.52 %*1.5507
=-38.02 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-23138.184/60851.7585
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-23138.184 / -24584.256) * (-24584.256 / -23787.432) * (-23787.432 / 9266.272) * (9266.272 / 94364.7385) * (94364.7385 / 60851.7585)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9412 * 1.0335 * -256.71 % * 0.0982 * 1.5507
=-38.02 %

Note: The net income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


D&D Pharmatech ROE % Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


D&D Pharmatech Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines